Exploring the UK’s evolving role in commercializing cell and gene therapies

“...the UK is strongly behind cell and gene therapy, and we have an excellent regulatory agency...”

Jokūbas Leikauskas, Editor, BioInsights, speaks to Matthew Durdy, CEO, Cell and Gene Therapy Catapult, about addressing key barriers to cell and gene therapy (CGT) commercialization, focusing on areas such as cost reduction, scalability, and adoption by the healthcare systems. They also discuss how the CGT landscape in the UK has evolved over the past decade, emphasizing the country’s global leadership potential in the field.

Please enter your email to access content Read now